Therefore, in order to find a weakness in BETi-resistant AML cells, some researchers tested a combined BETi with CDK7 inhibition treatment, and showed that targeting both BRD4 and CDK7 resulted in an interesting synergistic effect in vitro and in vivo, affecting BETi-resistant cell growth [86]. This evidence concerns the gene CDK7 and acute myeloid leukemia.